Juno Therapeutics Reports Second Quarter 2015 Financial Results
August 12, 2015 16:05 ET
|
Juno Therapeutics
-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial --
-- Transformative partnership with Celgene --
-- Substantial R&D progress with key acquisition integrations on...
Juno Therapeutics to Report Second Quarter 2015 Financial Results on Wednesday, August 12
August 05, 2015 16:05 ET
|
Juno Therapeutics
SEATTLE, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the second quarter of 2015 on Wednesday, August 12, 2015 after the close of...
Juno Announces Early HSR Clearance for Global Collaboration With Celgene
August 05, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
Juno Announces FDA Clearance of Investigational New Drug Application for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
July 30, 2015 16:39 ET
|
Juno Therapeutics
-- Multi-center, pivotal Phase 2 trial to begin in the near term --
SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on...
Juno Announces FDA Acceptance of Investigational New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
June 29, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, June 29, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
Juno Therapeutics to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
June 03, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, June 3, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentation at the Goldman Sachs 36th Annual Global Healthcare Conference at...
Juno Therapeutics Adds Antibody Engineering Capabilities Through Acquisition of X-BODY
June 02, 2015 07:30 ET
|
Juno Therapeutics
-- Transaction Accelerates Capabilities to Create Novel Fully Human CAR T and TCR Constructs --
-- Initial Payment of Approximately $21 Million in Cash and 439,265 Shares of Juno Stock...
Juno's Investigational CAR T Cell Product Candidate JCAR014 Demonstrates Encouraging Clinical Responses and Translational Insights in Patients With B-Cell Cancers
June 01, 2015 08:00 ET
|
Juno Therapeutics
SEATTLE, June 1, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. announced today that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging...
Juno's Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses in Patients With B-Cell Cancers
May 30, 2015 14:20 ET
|
Juno Therapeutics
SEATTLE, May 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) announced today that clinical data from its most advanced chimeric antigen receptor (CAR) T cell product candidate,...
Juno Therapeutics Appoints Dr. Hyam I. Levitsky as Chief Scientific Officer
May 28, 2015 16:01 ET
|
Juno Therapeutics
SEATTLE, May 28, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...